The Chemopreventive Agent Development Research Group (CADRG) promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.
Read more About the Chemopreventive Agent Development Research Group.
News and Events
Nucleoside Modified mRNA-LNP Therapeutics
Date Posted: June 12, 2024
Translational Advances in Cancer Prevention Agent Development (TACPAD) – 3rd Biennial Virtual Meeting
Date Posted: April 26, 2024
CAP-IT News - April 2024
Date Posted: April 22, 2024
Immuno-Oncology Translational Network (IOTN) Capstone Meeting
Date Posted: March 27, 2024
Rare Cancers Prevention and Interception Virtual Workshop
Date Posted: March 21, 2024